Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single‐arm, exploratory phase II trial
Cancer Medicine · 2024
DOI: 10.1002/cam4.70206 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, 2024. Verfasst von Qinglian Tang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Musculoskeletal Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China. Hauptthemen laut MEDLINE: Osteosarcoma, Methotrexate, Ifosfamide, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The poor overall survival of osteosarcoma (OS) underscores the need to explore new therapeutic avenues. Tumor necrosis rate (TNR) after neoadjuvant chemotherapy predicts prognosis.
Aims
The study was to investigate safety and activity of neoadjuvant chemotherapy with camrelizumab (a humanized antibody against PD‐1) in patients with resectable OS. Materials & Methods We conducted a prospective, single‐arm, exploratory phase II trial in OS patients. Eligible patients received camrelizumab combined with doxorubicin or liposomal doxorubicin, cisplatin, methotrexate, ifosfamide with mesna. Surgery was performed 12–14 days after neoadjuvant therapy and adjuvant therapy starting 2–3 weeks postoperatively. The primary endpoint was the rate of good tumor necrosis (TNR ≥90%) after neoadjuvant therapy, and the secondary outcomes were safety, 2‐year progression free survival and 2‐year overall survival.
Results
Seventy‐five patients were recruited to the study. Subsequently, 64 patients completed neoadjuvant therapy and underwent surgery. Thirty‐one patients (48.4%) have a good TNR to neoadjuvant therapy. With a median follow‐up of 22.4 months (range 2.2–44.9 months), the estimated 2‐year PFS was 69.6% and the estimated 2‐year overall survival was 89.4%. Grade 3 or 4 treatment‐related adverse events were noticed in 62.7% of the patients. Frequent grade 3 or 4 adverse events were decreased platelet count (45.3%), decreased white blood cell count (36%). No immune‐related serious adverse events were observed.
Discussion
Our study had limitations. First, it was limited by its non‐randomized design. Besides, stromal tumor‐infiltrating lymphocytes was comprehensively analyzed in this study.
Conclusions
This study demonstrated that amrelizumab combined with adriamycin, cisplatin, methotrexate, and ifosfamide in the neoadjuvant treatment of resectable OS was safe and tolerable. This combined therapeutic strategy may not increase TNR, but the long‐term survival benefit remains to be followed up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Musculoskeletal Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
- Department of pathology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
- Department of radiology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
ORCID-Profile: Qinglian Tang, Guohui Song
Zitieren
APA
Tang, Q., Zhang, X., Zhu, X., Xu, H., Song, G., Lu, J., Wu, H., Deng, C., Ai, F., Zhang, Y., & Wang, J. (2024). Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single‐arm, exploratory phase II trial. Cancer Medicine. https://doi.org/10.1002/cam4.70206
Vancouver
Tang Q, Zhang X, Zhu X, Xu H, Song G, Lu J, et al. Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single‐arm, exploratory phase II trial. Cancer Medicine. 2024. doi:10.1002/cam4.70206
BibTeX
@article{Tang2024,
author = {Tang, Qinglian and Zhang, Xinke and Zhu, Xiaojun and Xu, Huaiyuan and Song, Guohui and Lu, Jinchang and Wu, Hao and Deng, Chuangzhong and Ai, Fei and Zhang, Yingchun and Wang, Jin},
title = {Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single‐arm, exploratory phase II trial},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70206}
}
EUVIMED